Plexision

Plexision develops cellular biomarkers for personalized diagnostics and drug development in infectious diseases, solid organ transplantation, as well as immuno-oncology. Plexision’s team consists of highly-trained technologists, cytometrists, clinicians, scientists, bioentrepreneurs, and bioinformaticians. Plexision currently offers a wide array of lab-developed cell-based diagnostic tests for personalized patient care. Plexision’s first product, the FDA-approved PleximmuneTM blood test predicts transplant rejection. Plexision develops cellular biomarkers for personalized diagnosis and drug development in solid organ transplantation and immunological disorders. Plexision performs custom R and D projects aimed at integrating biomarker targets in all phases of drug development. NEW YORK— Diagnostics startup Plexision aims to cut down delays in testing for organ transplant rejection with an antigen-based blood test for early signs a patient's immune system is attacking the donated tissue. Plexision, a biotechnology company, which provides personalized diagnostic testing services for organ transplant patients has completed development of a six-hour blood test to predict organ transplant rejection - PlexAPRTM.